Happy to share review of zolbetuximab for #gastriccancer . Regulatory approval still awaited.
journals.sagepub.com/doi/full/10.11…

Zolbetuximab plus FOLFOX improved PFS and OS in patients with claudin 18.2 positive gastric/GEJ cancer in the SPOTLIGHT study. This is great news for us and our patients. Please stay tune for the detail. astellas.com/en/news/26821.
. #stomachcancer OncoAlert ESMO - Eur. Oncology ASCO

SPOTLIGHT study of #Zolbetuximab was just published in The Lancet. Achievement by global collaboration to establish new treatment option for #gastriccancer . thelancet.com/journals/lance… ILSON David Manish A. Shah Florian Lordick Sam Klempner Astellas Pharma US OncoAlert ASCO ESMO - Eur. Oncology

⭐️⭐️Two major announcements for (Her-2 negative) Gastric/GEJ cancer ⭐️⭐️⭐️

TWO trials have met their end points (PFS, OS) for front line treatment of metastatic gastric/GEJ cancer.

1) Zolbetuximab + Chemo for CLDN18.2 ➕
2) Pembro+Chemo

Cant wait for results!

It’s getting brighter for CLDN18.2+ gastric cancer 🌟 #GISCM
#GI23 SPOTLIGHT
Live now #ASCOPlenarySeries
GLOW 👉CAPOX +/- zolbetuximab
📌 n=507
📌 ⬆️ OS 14.4 v 12.1mHR 0.77, P=0.0118
📌 RR 54%v49%
➡️ chemo+zolbe is SOC for CLDN18.2+ stomach cancer
- same HR but still not sure…

#ESMO23
GASTFOX-PRODIGE 51 trial

Gastric/GEJ cancer first line
mFLOT(TFOX) vs FOLFOX

PFS➡️7.6 vs 6 mo
OS➡️15.0 vs 12.6 mo
ORR➡️66% vs 56.7%

💥New backbone SoC?

❓Question: Can we combine FLOT with ICI, trastuzumab, or Zolbetuximab

Presented by Dr. Aziz Zaanan

#Spotlight Zolbetuximab/Folfox superior to Placebo/Folfox (no Nivo) Most of patients had CPS<5 (need detailed data) #PFS 1ary obj #GI23 ASCO

🔦💡SPOTLIGHT: CLDN18.2 mAb zolbetuximab + mFOLFOX showed superior PFS and OS compared to placebo + placebo in CLDN18.2 high (75%+ staining) met #gastriccancer and #GEJcancer #GI23 @asco Kohei shitara OncoAlert

Updated results of SPOTLIGHT and GLOW trials at ESMO ASIA 2023: confirmation that addition of Zolbetuximab to chemotherapy in first line metastatic gastric cancer Claudin 18.2+ increases the mPFS and OS.

Press release for CLDN18.2+\HER2- ph3 SPOTLIGHT addition of zolbetuximab to 1L FOLFOX gastric/GEJ adenoca, n=566
Positive for PFS and OS 💡
📌 CLN18.2 positivity in almost 50%
➡️ look forward to the full data presentation
astellas.com/en/news/26821

Congrats~🎊 to patients with advanced GEJ & #GastricCancer & #SPOTLIGHT team Kohei shitara Florian Lordick ILSON David #zolbetuximab + mFOLFOX6 in tumors #HER2 (-) #CLDN18 .2 show ⬆️OS & PFS📈 vs SOC mFOLFOX6 met endpoints HR 0.75; mOS 18.2m vs 15.5m, p=0.005 🖊️87% had PD-L1 CPS<5

.Manish A. Shah describes the GLOW study of zolbetuximab + #chemotherapy in certain patients w/ advanced #gastriccancer or gastroesophageal junction #cancer , via #ASCO20 . bit.ly/2zAGia6

#SPOTLIGHT data by Kohei shitara at #GI23 : #Zolbetuximab +mFOLFOX6 as 1L for CLDN18.2+ HER2- advanced GC/GEJ
⬆️PFS and OS
↔️ORR
▶️TEAEs: nausea/vomiting (on target)
▶️CLDN18.2+ in 38.5% of pts, and PD-L1 CPS≥5 in 13.2%
First positive biomarker-selected ph3 trial in GC in>10 years

Zolbetuximab plus chemo is approved in Japan for patients with claudin 18.2 positive gastric cancer. New treatment option for our patients with #stomachcancer ! Approval pending in other countries.
astellas.com/en/news/29026
U.S. FDA Astellas Pharma US ASCO ESMO - Eur. Oncology OncoAlert

🏃🏻‍♂️trial in progress🤘🏼waging for 💜Zolbetuximab +/- GN in 1L Tx for CLDN18.2 (+) mPDAC🤞 #SPOTLIGHT looked promising! Near half accrued and globally accruing! Please ask your oncologist if this trial is available in your area! #PancreaticCancer Memorial Sloan Kettering Cancer Center MSKCC Center for Pancreatic Cancer Research #GI23 ASCO

1> The effectiveness of the Claudin18.2 monoclonal antibody alone was modest. In contrast, zolbetuximab showed substantial effectiveness in targeting cells with high Claudin18.2 expression, especially when used alongside chemotherapy.
However, osemitamab, which presumably has…

🔥Just published: Zolbetuximab meets primary endpoint in SPOTLIGHT trial as 1st treatment in CLAUDIN 18.2 positive #gastric cancer🔥
👉Phase-3 with 566 patients
💪great to see new options for🎯💊

ESMO - Eur. Oncology OncoAlert

Zolbetuximab gets approval for metastatic gastric cancer in Japan. Based upon Spotlight and Glow Trial data. Remember @usfda had denied them approval in Jan 2024, based upon quality control issues . Yakup Ergün Yüksel Ürün Axel Grothey Tanios Bekaii-Saab, MD Dr. Cathy Eng brunolarvol.eth

A Phase II Study of Zolbetuximab plus Nab-paclitaxel and Gemcitabine to Treat Metastatic Pancreatic Cancer mskcc.org/cancer-care/cl…
@sloan_kettering
Eileen M O’Reilly
@W_Park_MD

SPOTLIGHT trial:
🔘Combining zolbetuximab with mFOLFOX6 significantly improves progression-free and overall survival in CLDN18.2-positive, HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinoma patients.
🔘This combo may be a new first-line treatment…